Editor’s Pick: Paradigm Shift in the Management of Gynaecological Cancers - European Medical Journal


Editor’s Pick: Paradigm Shift in the Management of Gynaecological Cancers

| Download as | PDF
Katelijn Sap, *Philippe Van Trappen

No potential conflict of interest.

EMJ Oncol. ;3[1]:12-18.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


In this review we highlight novel aspects of diagnostic imaging in gynaecological cancers, the paradigm shift in the surgical management of certain female pelvic cancers, as well as potential new molecular targeted therapies. In the last decade, ultra-radical surgery has been shown to increase survival in  advanced ovarian cancer (OVC) when extended surgical procedures are included during primary  cytoreductive surgery or at interval debulking procedures after neoadjuvant chemotherapy. In cervical  cancer (CVC) and endometrial cancer (EMC) endoscopic (laparoscopic or robotic) operations have been shown to significantly reduce the morbidity without altering the cancer-related survival. Although the  sentinel lymph node concept is already established in early-stage vulvar cancer, its diagnostic accuracy in  EMC and CVC is still under debate. Novel molecular targeted therapies including blocking agents against new blood vessel formation (anti-angiogenesis) and polyadenosine diphosphate ribose polymerase inhibitors have been shown to prolong the progression-free survival in advanced OVC. Other molecular therapies, single or combined, are under investigation in OVC and EMC.

Please view the full content in the pdf above.